Understanding AOD 9604 Dosing in Research
AOD 9604 (Advanced Obesity Drug 9604) is a modified fragment of human growth hormone (hGH fragment 176-191) originally developed for metabolic research. It retains the fat metabolism activity of growth hormone without affecting IGF-1 levels, blood glucose, or growth parameters — making it a unique tool for lipid metabolism studies.
Mechanism of Action
AOD 9604 mimics the lipolytic action of natural growth hormone by stimulating the beta-3 adrenergic receptor pathway in adipose tissue. It enhances fat oxidation and inhibits lipogenesis without the diabetogenic or growth-promoting effects of full-length hGH. This specificity makes precise dosing protocols particularly important in research.
Research Dosing Protocols
Standard Subcutaneous Protocol
- Dose: 250-500mcg daily
- Frequency: Once daily, typically morning on empty stomach
- Administration: Subcutaneous injection (abdominal area preferred in studies)
- Duration: 12-24 week research cycles
Clinical Trial Dosing (Phase 2/3)
AOD 9604 underwent clinical trials in Australia where oral formulations were tested at doses of 1mg, 5mg, and 30mg daily. The oral bioavailability is significantly lower than subcutaneous, which explains the dose differences between routes.
Timing Considerations
Research protocols typically administer AOD 9604 in the morning on an empty stomach. While the peptide does not stimulate GH release, fasting administration appears to optimize the lipolytic response in adipose tissue based on study protocols.
AOD 9604 vs Full HGH Fragment
AOD 9604 is sometimes confused with hGH fragment 176-191. While they share the same amino acid sequence (positions 176-191 of growth hormone), AOD 9604 includes a specific tyrosine modification at the C-terminus that enhances its stability and biological activity. This distinction matters for accurate dosing as the two compounds may have different potencies.
Reconstitution
Reconstitute lyophilized AOD 9604 with bacteriostatic water. Using 2mL per 5mg vial yields 2,500mcg/mL. For a 300mcg dose, draw 0.12mL (12 units on insulin syringe). See our reconstitution guide.
Combination Research
Some research protocols study AOD 9604 alongside other metabolic peptides such as semaglutide or MOTS-C for complementary mechanisms of action on fat metabolism. See our AOD 9604 vs Semaglutide comparison.
Storage
Store lyophilized AOD 9604 at -20°C to 4°C. Reconstituted at 2-8°C, use within 3-4 weeks. See storage guide.
For research purposes only. AOD 9604 is a research compound. Visit COAs for purity verification.
Related Articles
All products are sold strictly for research purposes only. Not for human consumption.